Concise drug review: Azacitidine and decitabine

Oncologist

Volumn 18, Issue 5, 2013, Pages 619-624

  Derissen, Ellen J B ^a   Beijnen, Jos H ^a,b   Schellens, Jan H M ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Azacitidine; Decitabine; DNA methyltransferase inhibitor; Drug profile; Hypomethylating drug

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DNA METHYLATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; EPIGENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SKIN TOXICITY; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA;

AZACITIDINE; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; DRUG PROFILE; HYPOMETHYLATING DRUG;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MYELODYSPLASTIC SYNDROMES;

EID: 84878186386     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0465     Document Type: Article

References (41)

1. Beran M. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Int J Hematol 2000;72:139-150.
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higherrisk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10: 223-232.
3. Itzykson R, Fenaux P. Optimizing hypomethylating agents in myelodysplastic syndromes. Curr Opin Hematol 2012;19:65-70.
4. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006;106:1794-1803.
5. Lübbert M, Suciu S, Baila L et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29: 1987-1996.
6. Kantarjian HM, Thomas XG, Dmoszynska A. et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients withnewly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670-2677.
7. Quintás-Cardama A, Ravandi F, Liu-Dumlao T et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012;120:4840-4845.
8. Summary of product characteristics: Vidaza 25 mg/mL powder for suspension for injection. Available at http://www.ema.europa.eu/docs. Accessed September 11, 2012.
9. Lyons RM, Cosgriff TM, Modi SS et al. Hematologicresponseto three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27:1850-1856.
10. Approvedlabelingdacogen(decitabine) for injection. Available at http://www.accessdata.fda.gov. Accessed October 2, 2012.
11. Steensma DP, Baer MR, Slack JL et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27: 3842-3848.
12. Cheson BD, Greenberg PL, Bennett JM et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
13. Silverman LR, Fenaux P, Mufti GJ et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117:2697-2702.
14. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429-2440.
15. Silverman LR, McKenzie DR, Peterson BL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-3903.
16. Rüter B, Wijermans PW, Lübbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006; 106:1744-1750.
17. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010;24:317-330.
18. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009;15:3938-3946.
19. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13.
20. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: Molecular mechanisms and clinical implications. Clin Cancer Res 2009;15:3927-3937.
21. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-5495.
22. Kantarjian HM, O'Brien S, Shan J et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109: 265-273.
23. Itzykson R, Thépot S, Quesnel B et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117: 403-411.
24. Breccia M, Loglisci G, Cannella L et al. Application of French prognostic score to patients with International Prognostic Scoring System intermediate- 2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to evaluate overall survival and rate of response. Leuk Lymphoma 2012;53:982-983.
25. van der Helm LH, Alhan C, Wijermans PW. et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch Azacitidine Compassionate Named Patient Programme. Br J Haematol 2011;155:599-606.
26. Itzykson R, Kosmider O, Cluzeau T et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:1147-1152.
27. Itzykson R, Fenaux P. Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents. Leuk Lymphoma 2012;53:760-762.
28. Prébet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29:3322-3327.
29. Jabbour E, Garcia-Manero G, Batty N. et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010; 116:3830-3834.
30. Prébet T, Gore SD, Thépot S et al. Outcome of acutemyeloidleukaemiafollowing myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol 2012;157:764-766.
31. Borthakur G, Ahdab SE, Ravandi F et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008;49:690-695.
32. Sekeres MA, Tiu RV, Komrokji R et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012;120:4945-4951.
33. Zhao M, Rudek MA, He P et al. Quantification of 5-azacytidine in plasma by electrospray tandem massspectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:81-88.
34. Patel K, Guichard SM, Jodrell DI. Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies J Chromatogr B Analyt Technol Biomed Life Sci 2008;863:19-25.
35. Marcucci G, Silverman L, Eller M., et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005;45:597-602.
36. Cashen AF, Shah AK, Todt L et al. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008;61:759-766.
37. Chen Y, Liu L, Laille E et al. In vitro assessment ofcytochromeP450inhibitionandinduction potential of azacitidine. Cancer Chemother Pharmacol 2010;65:995-1000.
38. Troetel WM, Weiss AJ, Stambaugh JE et al. Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man. Cancer Chemother Rep 1972;56:405-411.
39. Israili ZH, Vogler WR, Mingioli ES et al. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res 1976;36:1453-1461.
40. Batty GN, Kantarjian H, Issa JP et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk 2010;10:205-210.
41. Santini V, Fenaux P, Mufti GJ et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010;85: 130-138.